Are there potential problems with generic substitution of antiepileptic drugs? A review of issues

Seizure : the Journal of the British Epilepsy Association
Pamela CrawfordG Krämer

Abstract

In response to increasing cost pressures, healthcare systems are encouraging the use of generic medicines. This review explores potential problems with generic substitution of antiepileptic drugs (AEDs). A broad search strategy identified approximately 70 relevant articles. Potential problems with generic substitution included: The limited evidence (mainly case reports with some pharmacokinetic studies) appears to support these concerns for older AEDs. As a result, restrictions on use of specific generic AEDs are in place in some countries and recommended by some lay epilepsy organisations. As more AEDs lose patent protection, it is important to examine the question of whether generic substitution may pose problems for patients with epilepsy, and whether there should be safeguards to ensure that both physician and patient are informed when generic substitution occurs.

References

Dec 2, 1977·European Journal of Clinical Pharmacology·B RambeckE Stenzel
Dec 19, 1975·European Journal of Clinical Pharmacology·M J StewartA C Ramsay
Dec 19, 1975·European Journal of Clinical Pharmacology·P J PentikäinenS M Elfving
Aug 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·I Soryal, A Richens
Feb 1, 1991·The Journal of Pharmacy and Pharmacology·R HartleyW I Forsythe
Nov 1, 1990·Neurology·M R NuwerB J Wilder
Aug 1, 1985·The Journal of Pharmacy and Pharmacology·M R HirjiJ C Mucklow
May 1, 1986·Journal of Clinical Pharmacology·P P Lamy
May 1, 1994·Epilepsia·D H RosenbaumJ A French
Dec 1, 1993·Neurology·J T GilmanM Duchowny
Mar 1, 1996·Seizure : the Journal of the British Epilepsy Association·P CrawfordA Stewart
Oct 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P A Meredith
Jul 10, 1998·Pharmacopsychiatry·E Sherwood BrownT Suppes
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·F M Besag
Jun 13, 2002·Epilepsia·Dominic C Heaney, Charles E Begley
Jun 13, 2002·Epilepsia·Dominic C HeaneyMichael T Halpern
Jul 24, 2004·CNS Drugs·Barbara C Jobst, Gregory L Holmes
Dec 8, 2004·Epilepsy & Behavior : E&B·Andrew N Wilner

❮ Previous
Next ❯

Citations

Feb 18, 2014·International Journal of Clinical Pharmacy·Ahmed AwaisuRaja Barazi
Jul 21, 2009·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Richard A Marasco, R Eugene Ramsay
Jul 16, 2009·Journal of Neurology·Marc MaliepaardFrits J F Lekkerkerker
Aug 27, 2009·Therapeutics and Clinical Risk Management·Bernhard J SteinhoffGünter Krämer
Jun 12, 2009·Current Neurology and Neuroscience Reports·Barry E Gidal
Jan 17, 2007·Medical Care·Richard L Kravitz
Jun 15, 2011·Journal of Neurology·Eugen TrinkaMartin Graf
Mar 3, 2011·International Journal of Clinical Pharmacy·Chee Ping ChongAsrul Akmal Shafie
Apr 16, 2011·European Journal of Clinical Pharmacology·Marc MaliepaardAndré J Elferink
Nov 26, 2010·Expert Review of Neurotherapeutics·Josemir W SanderJürgen Bauer
Aug 12, 2009·Expert Opinion on Pharmacotherapy·Mei Sheng DuhPaul E Greenberg
Mar 5, 2008·Current Medical Research and Opinion·Jacques LeLorierOdile Sheehy
Jun 10, 2009·Current Medical Research and Opinion·Pierre Emmanuel ParadisMei Sheng Duh
Jun 12, 2008·Current Medical Research and Opinion·Jérôme VialDidier Thiébaut
Jun 29, 2010·Epilepsy & Behavior : E&B·Sandra L HelmersDavid M Labiner
Nov 26, 2009·La Presse médicale·Pascal Le Corre
Jul 21, 2009·Epilepsy & Behavior : E&B·Ryan N HansenSean D Sullivan
Oct 11, 2008·Epilepsy & Behavior : E&B·Tania Beltran PapsdorfKore Liow
Sep 16, 2008·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Wim Van PaesschenLieven Lagae
Jul 1, 2008·Epilepsy & Behavior : E&B·Michel J BergKenneth J Tomaszewski
May 13, 2008·Journal of Pharmaceutical and Biomedical Analysis·Dione Marçal LimaEliana Martins Lima
Jun 1, 2007·Epilepsy & Behavior : E&B·G KrämerG Zaccara
Apr 17, 2007·Lancet Neurology·Dominic C Heaney, Josemir W Sander
Dec 8, 2015·The International Journal of Risk & Safety in Medicine·E PasternakV Merculov
Dec 23, 2008·Epilepsia·Barry E Gidal, Torbjörn Tomson
Dec 17, 2009·Acta Clinica Belgica·F R Heller, A G Dupont
Dec 1, 2010·CNS Neuroscience & Therapeutics·Julie Eve DesmaraisHoward C Margolese
Jun 12, 2010·Journal of the American Academy of Nurse Practitioners·Megan Weigel Barrett
Jun 4, 2013·Epilepsy Research·Ryan N HansenSean D Sullivan
Oct 28, 2011·Epilepsy Research·Vishal PatelRoy G Beran
Oct 3, 2015·Internal Medicine Journal·R G Beran

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.